Decreased risk of anxiety in diabetic patients receiving Glucagon-like peptide-1 receptor agonist: a Nationwide, Population-Based Cohort Study
In patients with T2DM and chronic liver disease attributed to MASLD, the risk of major adverse liver outcomes after GLP-1RA treatment over 10 years fails to decrease (15.8% vs
For some people, they are debilitating enough to require dose reduction or discontinuation
These associations remained statistically significant even after adjusting for other factors
The decline in GHK plasma levels with agefrom 200 ng/mL to 80 ng/mLcorrelates with the general decrease in regenerative capacity
Moreover, ROS exerts an important effect on microglia as the second messenger, modifying inflammatory gene transcription and, consequently, amplifying the inflammation